The Department of Health says it is moving quickly to list the anti-CGRP monoclonal antibody galcanezumab (Emgality) on the PBS for prevention of migraine. In response to questions in parliament from Senators on delays in progression of listing approvals listing for anti-migraine drugs, officials told a Senate Estimates hearing that it was moving forward as ...
CGRP inhibitor progressing to PBS listing within months
By Michael Woodhead
30 Mar 2021